London
· Delayed Price · Currency is GBP · Price in SEK Xspray Pharma AB Statistics
Total Valuation
Xspray Pharma AB has a market cap or net worth of GBP 91.02 million. The enterprise value is 87.98 million.
| Market Cap | 91.02M |
| Enterprise Value | 87.98M |
Important Dates
The next estimated earnings date is Wednesday, February 12, 2025.
| Earnings Date | Feb 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +36.35% |
| Shares Change (QoQ) | +3.12% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 25.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 2.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.63 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.97 |
Financial Position
The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.06.
| Current Ratio | 1.90 |
| Quick Ratio | 1.46 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.17 |
| Interest Coverage | -9,630.04 |
Financial Efficiency
Return on equity (ROE) is -41.42% and return on invested capital (ROIC) is -22.57%.
| Return on Equity (ROE) | -41.42% |
| Return on Assets (ROA) | -21.08% |
| Return on Capital (ROIC) | -22.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -790,958 |
| Employee Count | 26 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.09% in the last 52 weeks. The beta is 0.82, so Xspray Pharma AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | +8.09% |
| 50-Day Moving Average | 39.48 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 47.68 |
| Average Volume (20 Days) | 711 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.01M |
| Pretax Income | -18.99M |
| Net Income | -18.98M |
| EBITDA | -16.52M |
| EBIT | -17.01M |
| Earnings Per Share (EPS) | -0.58 |
Balance Sheet
The company has 5.50 million in cash and 2.47 million in debt, giving a net cash position of 3.03 million.
| Cash & Cash Equivalents | 5.50M |
| Total Debt | 2.47M |
| Net Cash | 3.03M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 43.08M |
| Book Value Per Share | 1.28 |
| Working Capital | 3.53M |
Cash Flow
In the last 12 months, operating cash flow was -14.23 million and capital expenditures -514,499, giving a free cash flow of -14.74 million.
| Operating Cash Flow | -14.23M |
| Capital Expenditures | -514,499 |
| Free Cash Flow | -14.74M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Xspray Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.35% |
| Shareholder Yield | -36.35% |
| Earnings Yield | -20.86% |
| FCF Yield | -16.20% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |